ESMO: Mirati’s Adagrasib Appears To Maintain CRC Edge In KRAS Race
The company is reporting strong ORR, durability and PFS at ESMO in heavily pretreated colorectal cancer, an indication where Amgen’s Lumakras has struggled.
You may also be interested in...
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.
Deal Snapshot: The Nobel Prize winner co-founded biotech can extend its cash runway into 2025, while Roche gains access to an immunotherapy with potential to treat a wide range of cancers.
Newly launched with a $90m series A funding round, the company is taking the idea behind KRAS G12C inhibitors to another level.